Drug Discovery Featured Articles & Applications

  1. De-Risking U.S. Market Entry Of Early-Stage Therapeutics 10/8/2025

    One of the most effective ways to de-risk a therapeutic program is to enter preclinical development with a regulatory mindset and a strategic, data-driven approach.

  2. Answering The Call To Develop Novel Drugs For Rare Diseases 10/6/2025

    Standing out in the drug development crowd requires entrepreneurial thinking, accelerating innovation, financial considerations, and a commitment to science.

  3. CMC For Long-Acting Injectables For TB 10/3/2025

    Long-acting injectables are a potential treatment alternative for tuberculosis, but they require key development considerations from a chemistry, manufacturing, and controls perspective.

  4. What If We Had Just One Developability Parameter? 10/3/2025

    Research suggests years-long stability studies that gobble up material can be reduced to a single day using milligram quantities.

  5. Could iPSCs Be The Answer To Treating CNS Disorders? 10/2/2025

    We caught up with Jeffrey M. Brown, Ph.D., MBA, scientific advisor at Neurizon Therapeutics, to discuss how iPSCs could be the key to treating CNS disorders.

  6. Tyra Crystallizing The First Oral FGFR3 Therapy For Achondroplasia 9/30/2025

    Tyra Biosciences is using its SNÅP drug discovery platform to develop dabogratinib, the first oral FGFR3-selective therapy for achondroplasia, currently recruiting patients in Phase 2 trials.

  7. Pros And Cons Of In Silico Target-Drug Dynamics 9/29/2025

    In silico target-drug dynamics offer unprecedented speed, scalability, and cost-efficiency, but there are risk factors of overreliance, regulatory uncertainty, and data bias.

  8. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 2) 9/19/2025

    Part 2 of 2 - An Interview with Alex (Aleksandrs Zavoronkovs) Zhavoronkov, Ph.D. , Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine.

  9. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 1) 9/18/2025

    An Interview with Alex Zhavoronkov, Ph.D. Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine. Founded in 2014, Insilico Medicine, is one of the earliest AI-driven biotech companies and one of the few who have pipeline drugs in Phase II trials.

  10. Expanding A Single Mechanism Through Genetic Logic And Clinical Observation 9/12/2025

    With the right biology, a single mechanism can open multiple clinically meaningful avenues for oncology drug development. Step Pharma CEO discusses their clinical development programs for oncology.